Literature DB >> 16785060

Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.

M Bitan1, R Or, M Y Shapira, M Aker, I B Resnick, A Ackerstein, S Samuel, S Elad, S Slavin.   

Abstract

Reduced intensity conditioning has been suggested as a desirable therapeutic modality for the treatment of patients with malignant and nonmalignant indications, but it seems particularly attractive for patients with Fanconi anemia due to their increased sensitivity to chemoradiotherapy. Between November 1996 and September 2003, 7 patients (1 male and 6 female; age range, 3-31 years; median age, 9.5) were conditioned with a fludarabine-based protocol for stem cell transplantation without radiation. In vivo T-cell depletion was accomplished with anti-thymocytic globulin or Campath-1H (alemtuzumab). Graft-versus-host disease prophylaxis consisted of low-dose cyclosporine alone. Eight transplantations were carried out for 7 patients using bone marrow, peripheral blood, and/or cord blood as sources of stem cells. All patients received transplants from HLA-A, -B, -C, and -DR matched donors, 5 from family members and 2 from matched unrelated donors. One patient did not engraft her first matched unrelated donor and underwent a second transplantation from another matched unrelated donor, after which she engrafted well. All 7 patients are alive and well, fully reconstituted with donor cells, and with 100% performance status. In conclusion, fludarabine-based preparative protocols are well tolerated, facilitate rapid engraftment with minimal toxicity, and should be considered an essential component of choice for patients with Fanconi anemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785060     DOI: 10.1016/j.bbmt.2006.03.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

Review 1.  Hematopoetic stem cell transplantation in children.

Authors:  Mehmet Akif Yeşilipek
Journal:  Turk Pediatri Ars       Date:  2014-06-01

2.  Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature.

Authors:  Thomas H Beckham; Jonathan Leeman; Chiaojung Jillian Tsai; Nadeem Riaz; Eric Sherman; Bhuvanesh Singh; Nancy Lee; Sean McBride; Daniel S Higginson
Journal:  Head Neck       Date:  2019-01-11       Impact factor: 3.147

3.  Low-dose irradiation prior to bone marrow transplantation results in ATM activation and increased lethality in Atm-deficient mice.

Authors:  J Pietzner; B M Merscher; P C Baer; R P Duecker; O Eickmeier; D Fußbroich; P Bader; D Del Turco; R Henschler; S Zielen; R Schubert
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

Review 4.  Cord blood transplantation for bone marrow failure syndromes: state of art.

Authors:  Simona Pagliuca; Annalisa Ruggeri; Régis Peffault de Latour
Journal:  Stem Cell Investig       Date:  2019-12-05

5.  Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.

Authors:  Mouhab Ayas; Wael Saber; Stella M Davies; Richard E Harris; Gregory A Hale; Gerard Socie; Jennifer LeRademacher; Monica Thakar; H Joachim J Deeg; Amal Al-Seraihy; Minoo Battiwalla; Bruce M Camitta; Richard Olsson; Rajinder S Bajwa; Carmem M Bonfim; Ricardo Pasquini; Margaret L Macmillan; Biju George; Edward A Copelan; Baldeep Wirk; Abdullah Al Jefri; Anders L Fasth; Eva C Guinan; Biljana N Horn; Victor A Lewis; Shimon Slavin; Polina Stepensky; Marc Bierings; Robert Peter Gale
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

Review 6.  Stress and DNA repair biology of the Fanconi anemia pathway.

Authors:  Simonne Longerich; Jian Li; Yong Xiong; Patrick Sung; Gary M Kupfer
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

7.  Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

Authors:  Mouhab Ayas; Mary Eapen; Jennifer Le-Rademacher; Jeanette Carreras; Hisham Abdel-Azim; Blanche P Alter; Paolo Anderlini; Minoo Battiwalla; Marc Bierings; David K Buchbinder; Carmem Bonfim; Bruce M Camitta; Anders L Fasth; Robert Peter Gale; Michelle A Lee; Troy C Lund; Kasiani C Myers; Richard F Olsson; Kristin M Page; Tim D Prestidge; Mohamed Radhi; Ami J Shah; Kirk R Schultz; Baldeep Wirk; John E Wagner; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-23       Impact factor: 5.742

8.  Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.

Authors:  M S Thakar; P Kurre; R Storb; M Kletzel; H Frangoul; M A Pulsipher; W Leisenring; M E D Flowers; B M Sandmaier; A Woolfrey; H-P Kiem
Journal:  Bone Marrow Transplant       Date:  2010-06-28       Impact factor: 5.483

9.  HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide.

Authors:  Carmem M Bonfim; Carlos R de Medeiros; Marco A Bitencourt; José Zanis-Neto; Vaneuza A M Funke; Daniela C Setubal; Jefferson Ruiz; Jean E Sanders; Mary E D Flowers; Hans-Peter Kiem; Rainer Storb; Ricardo Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2007-10-18       Impact factor: 5.742

Review 10.  Fanconi anemia.

Authors:  Allison M Green; Gary M Kupfer
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.